Risk factors
NextCure (NXTC) risk factors
Item 1A of every NextCure, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors62 risks3 new7 dropped8 reworded
NextCure discloses a going concern warning with $41.8 million in cash insufficient for a year and an accumulated deficit of $436.0 million.
Filed Mar 05, 2026 - FY2024 10-K risk factors66 risks
NextCure is a clinical-stage biopharmaceutical company with an accumulated deficit of $380.1 million as of December 31, 2024. The company has prioritized the development of LNCB74, initiating its first clinical trial in January 2025. Manufacturing operations were paused in March 2024 following a restructuring, relying on third-party partners.
Filed Mar 06, 2025